GLP-1s have become half of the UK diabetes budget. Here is what the prescribing data shows.
Two years ago the GLP-1 story was a supply story – Shortages, rationing, pharmacies turning patients away. Today it is a spending story. Across the four UK nations, primary care prescribing for diabetes and obesity reached £2.39bn in the latest twelve months, up 15% on the year before. Half of that, £1.19bn, is now GLP-1 and dual agonists. That class has more than doubled in cost in a single year.